Human PAC1 antibodies
AssigneeAmgen Inc.
InventorsCen Xu, Agnes Eva Hamburger
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
Claims15
An isolated humanized or fully human monoclonal antibody that specifically binds to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC 1), wherein the isolated humanized or fully human monoclonal antibody comprises (i) a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, and (ii) a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein CDRH1 comprises the sequence of SEQ ID NO:
- 257 or 258;
- CDRH2 comprises the sequence of SEQ ID NO:
- 259, 260, or 261;
- CDRH3 comprises the sequence of SEQ ID NO:
- 262;
- CDRL1 comprises the sequence of SEQ ID NO:
- 251 or 252;
- CDRL2 comprises the sequence of SEQ ID NO:
- 253, 254, or 255;
- and CDRL3 comprises the sequence of SEQ ID NO:
- 256.
Dependencies are inferred from the claim text.